U.S. Markets open in 5 hrs 32 mins

ProMetic Life Sciences Inc. (PLI.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
1.46+0.03 (+2.10%)
At close: 4:00PM EDT

ProMetic Life Sciences Inc.

440, Boulevard Armand-Frappier
Suite 300
Laval, QC H7V 4B4
Canada
450-781-0115
http://www.prometic.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Mr. Pierre Laurin B.Sc.Pharm., M.Sc.Chief Exec. Officer, Pres and Non-Independent Director1.14MN/A56
Mr. Bruce Pritchard BA, CA, FioDCOO & CFO894.49kN/AN/A
Mr. Patrick Sartore B.Sc., LLBChief Legal Officer and Corp. Sec.582.25kN/AN/A
Dr. John Moran M.D., FRACP, FACP, FACPEChief Medical Officer and Director629.14kN/A71
Mr. Frédéric DumaisSr. Director of Communications & Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. The company offers its technology platform for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer. It operates in two segments, Small Molecule Therapeutics and Protein Technology. The Small Molecule Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, metabolic syndrome and its resulting type 2 diabetes, cystic fibrosis related diabetes, and Alström syndrome. The Protein Technology segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma; bioseparation technologies and products, including Mimetic Ligand purification platform for the pharmaceutical and medical companies; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

Corporate Governance

ProMetic Life Sciences Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.